Safety profile of recombinant canarypox HIV vaccines (Q47245576)

12 January 2018

title

Safety profile of recombinant canarypox HIV vaccines (English)

1 reference

12 January 2018

author

Guy de Bruyn

1

1 reference

12 January 2018

Lawrence Corey

9

Lawrence Corey

1 reference

12 January 2018

6

Sharon E Frey

1 reference

12 January 2018

Thomas G. Evans

8

Thomas G Evans

1 reference

12 January 2018

Marnie L Elizaga

5

Marnie L Elizaga

1 reference

12 January 2018

Michael C Keefer

10

Michael C Keefer

1 reference

12 January 2018

author name string

Anthony J Rossini

2

1 reference

12 January 2018

Ya-Lin Chiu

3

1 reference

12 January 2018

Drienna Holman

4

1 reference

12 January 2018

Donald Burke

7

1 reference

12 January 2018

language of work or name

English

0 references

publication date

1 January 2004

1 reference

12 January 2018

published in

Vaccine

1 reference

12 January 2018

volume

22

1 reference

12 January 2018

page(s)

704-713

1 reference

12 January 2018

issue

5-6

1 reference

12 January 2018

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Vaccine safety: risk communication--a global perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Of floors and ceilings--defining, assuring, and communicating vaccine safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Safety of revaccination with pneumococcal polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Adverse reactions to polyvalent pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Side effects from influenza vaccination: differences between returned and random surveys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Evaluation of canarypox-induced CD8(+) responses following immunization by measuring the effector population IFNgamma production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Immunisation with canarypox virus expressing rabies glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

Vaccination and Revaccination with Polyvalent Pneumococcal Polysaccharide Vaccines in Adults and Infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.023

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2003.08.023

1 reference

12 January 2018

PubMed ID

14741163

1 reference

12 January 2018